FANGZHOU Aktie

 

Mr. Wang succeeds former CEO Mr. Xie Fangmin and steps into the leadership role following a milestone year for the Company....

Fangzhou reported its 2025 annual results, posting strong revenue growth and achieving full-year profitability....

The partnership aims to accelerate the digital transformation and enhancement of chronic disease services through the application of AI....

AU000000GMD9 SG1M49904634 CA23344H1091 NZMLNE0001S0 KYG2S85A1045 AU0000066508 US58844R8842 KYG549581067 GB00BJL1ZF49 HK0000504214 GB00BPJHZ015 GB00BYYJL418 GB00BLH32M40 MHY622674098 JP3868500004 CA7469601032 GB00BN33TR63 AU0000119307 CA1358711010 KYG9898S1075 CA92834E3068 US69346N1072 SG1W55939399 KYG9898C1024 CA82938H1073 JP3601800000 SE0015949946 PLCLDTC00019 CA74739G1072 CNE1000076P8 US39813G1094 AU000000ALI3 JP3292900002 BMG2233G2014 PLGRMID00019 AU0000122251 GB00BMYX7295 BMG6682J1036 US6915436074 PLSTRWI00019 CA87402A1084 JP3759800000 KYG5340S1093 CA76611L2030 PLBKDGM00019 SE0010245373 HK0000544194 PLGNMTC00017 US4404071049 KYG6981F1090 AU0000079212 KYG2929M1087 SG1CI9000006 US29445S1006 KYG4066M1151 VGG0542G1028 SE0026820854 KYG009701064 US03464Y1082 US98955N2071 SG1EB6000000 US20451Q1040 NO0013711739 GB00BMDXQ672 US54572F1012 CA94357L1058 GB00BTXYPJ53 CNE1000040M1 CNE1000031F4 IT0005453003 SE0015988274 PLCRTCH00017 US09549B1044...

GUANGZHOU, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, received prominent industry recognition at the “Digital Intelligence Powering Guangdong” 2026 Members Conference in Guangzhou, as the industry association highlighted its MaaS (Medicine as a Service) platform as a template for the next phase of Internet healthcare development....

The XS LLM integrates five intelligent agents into a closed-loop system covering the full chronic disease management cycle....

Fangzhou Wins Tencent Health 'AI-Powered Future Award' as MaaS Platform Drives AI Chronic Care....

Fangzhou expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30%...

Fangzhou plans to allocate approximately 90% of the net proceeds to accelerate development of the Company's AI-driven chronic disease management platform....

Yesterday, FANGZHOU JIANKE (06086.HK) crossed the finish line up 33% following the issuance of a positive profit alert. A subsequent announcement of a nearly 12% discounted top-up placement, however, sent the company's stock price tumbling by 10.6% at open today (27th). After dropping to a bottom of HKD3.12 at one point, it ......

FANGZHOU JIANKE (06086.HK) announced a top-up placement of 45.181 million shares (around 3.26% of its enlarged issued share capital) at a placement price of HKD3.32 per share, about an 11.94% discount to its previous closing price.The total and net proceeds are expected to be HKD150 million and HKD144 million, respectively. Arou......

Unterbrechnung des Handels von im Spezialistenmodell der Fortlaufenden Auktion gehandelten Wertpapieren. Aufgrund technischer Probleme wird der Handel in den unten benannten, vom Quoteverpflichteten MWBMU (MWB FAIRTRADE WERTPAPIERHANDELSBANK AG) betreuten Wertpapieren unterbrochen. Bestehende Orders werden nicht geloescht. Sollten Sie Rueckfragen haben, wenden Sie sich bitte an Cash Markets Operations unter der Telefonnummer +49-69-211-11400 AU0000318552 BMG3775G1539 CA00288K1084 CA00783M1041 CA03822G1046 CA04041C1068 CA0589451065 CA05973U1057 CA09263C1068 CA0969181076 CA09858C1077 CA12683R1091 CA21036D1050 CA30233X1033 CA4230061059 CA42804X3058 CA4349221008 CA4662971080 CA50214W1068 CA50244E1007 CA50244Q1037 CA5759771036 CA58769H1010 CA58933J1084 CA59101B1094 CA6249381063 CA64108U1003 CA64112T1075 CA6539521014 CA67010P1018 CA6749151032 CA68390F1018 CA7269161096 CA8010MA1047 CA80687R1029 CA81762A1057 CA8269461056 CA83572B1094 CA8629461002 CA8829291027 CA88355G...

Fangzhou Inc. and Tencent Healthcare jointly launched a comprehensive “AI+Chronic Disease Management” solution....

Fangzhou was recognized with the “Social Responsibility Golden Bull Award”....

Fangzhou was named an “Outstanding Strategic Health Ecosystem Partner,” recognizing its role in advancing digital innovation in chronic disease management....

Fangzhou was presented with a Generative AI Service Filing Certificate at the first Guangdong Provincial LLM Filing Conference....

Fangzhou and Fosun Pharma plan to build partnership in AI-powered chronic disease management, initially focused on psoriasis and other autoimmune condition...

Fangzhou plans to expand its "AI + Weight Management" ecosystem through broader applications, data-driven innovation, and cross-industry collaboration....

Fangzhou's “XingShi” Large Language Model (“XS LLM”) was featured by Nature News....

was recognized as an “Outstanding Growth Story in Hong Kong Stocks”...